October 6, 2015

ESD: A Precise, Minimally Invasive Option for Patients with Early Gastrointestinal Cancers

Endoscopic submucosal dissection is gaining popularity


Endoscopic submucosal dissection (ESD), a technique developed in Japan, has made its way to the United States, where it is offering a valuable alternative to the risks and complications associated with traditional surgical removal of early stage gastrointestinal tumors.


Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

ESD is performed by first introducing an endoscope through the mouth of the patient and into the esophagus or stomach. Through the endoscopy devices, experts can then dissect and remove the cancer from the gastrointestinal wall and take it out the patient’s mouth. This allows for complete removal of the cancer while allowing the patient to keep their esophagus/stomach and avoid traditional surgery. This same technique can be used to remove tumors of the colon through a colonoscope.

“In essence, ESD is operating through an endoscope to precisely remove early tumors, allowing the patient to keep their native organ, and avoid the significant morbidity and quality of life impairment associated with radical surgical resections,” says Amit Bhatt, MD, a gastroenterologist at Cleveland Clinic, who recently published a paper with his colleagues on indications and techniques for ESD in the American Journal of Gastroenterology.

Advantages of ESD

Traditional endoscopic mucosal resection has to remove tumors greater than 2 cm in pieces, meaning small amounts of tumors could be left behind, and it is hard to assess if the tumor is completely removed.


“In ESD, as the tumor is removed in one-piece, similar to a surgical resection, the pathologist can make a very accurate assessment of whether the entire cancer has been removed,” Dr. Bhatt says.


Bringing ESD from Japan to Cleveland

Thanks to grants from the American Society for Gastrointestinal Endoscopy and American College of Gastroenterology, Dr. Bhatt has completed extensive ESD training in Japan, where the technique was pioneered to address the country’s high incidence of gastric cancers. More than 50 percent of gastric cancers are caught early in Japan due to widespread screening programs. The country’s focus of improving treatment of early gastric cancer spurred the development of ESD. After ESD was proven to be a highly effective treatment option for gastric cancer, the technique was successfully extended to esophageal and colonic tumors.

Although the incidence of lung, breast and prostate cancers exceeds that of gastrointestinal cancers in the United States, gastrointestinal cancers still carry a significant burden here.

“Mirroring the increase in obesity and gastroesophageal reflux disease, the incidence of esophageal adenocarcinoma has rapidly risen in the Western world. Through increased awareness and screening of at-risk patients, we expect the number of patients diagnosed with early esophageal cancer is going to get larger,” Dr. Bhatt says. “While esophagectomy is effective from a curative standpoint because the esophagus lies within the chest cavity, an esophagectomy can be a morbid procedure and many patients may not be ideal candidates for the surgery.”

ESD in practice

Dr. Bhatt and his colleagues recently performed a curative ESD resection of a 4-cm cancer at the gastroesophageal junction in an older male who had recently undergone coronary artery bypass graft surgery and was not a candidate for esophagectomy.

The major difference between surgery and ESD is that “we can only resect the primary tumor itself with ESD,” he notes. “We can’t resect any lymph nodes. Part of understanding indications for this technique is knowing when a tumor has grown to the size or aggressiveness in which there is a chance that it has spread to the lymph nodes.”


Japanese data on thousands of specimens has enabled the characterization of patients whose risk of lymph node spread is extremely low and are candidates for ESD resection – data that Dr. Bhatt cites in his recent publication.

“For example, for a well-differentiated superficial gastric tumor without an ulcer, we can resect the tumor regardless of its size,” he explains. “However, if the tumor is greater than 3 cm and invades deeper into the submucosa, then surgery is probably the best option.”

Multidisciplinary assessment is critical

Dr. Bhatt stresses the importance of a multidisciplinary evaluation involving a gastroenterologist, surgeon and oncologist to determine the best treatment for a patient with an early lesion who might be a candidate for ESD. “Many of these patients can have their tumors resected with endoscopy and have the same long-term outcomes as surgical resection,” he says. “The procedure is less invasive, cost-effective and preserves the quality of life.”

He notes that ESD is a technically difficult procedure to learn and perform well. “You want to make sure the person doing it is adequately trained, and has a track record of success with it.”

Related Articles

Dr. Jagadeesh at Cleveland Clinic
February 28, 2024
Treating Patient with Systemic T-Cell Lymphoma and Graft-Versus-Host Disease

A case study on the value of access to novel therapies through clinical trials

Doctor measuring patient's waist size
February 26, 2024
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

February 7, 2024
Advances in Bone Marrow Transplant Have Improved Outcomes in Fanconi Anemia

Overall survival in patients treated since 2008 is nearly 20% higher than in earlier patients

February 5, 2024
Haploidentical Bone Marrow Transplant Has Durable Engraftment in Patients With Sickle Cell Disease

Two-year event-free survival comparable to matched sibling donor myeloablative transplant

February 1, 2024
Possibilities of CRISPR Technology (Podcast)

Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors

January 30, 2024
Gene Therapy Trials Show Positive Results in Sickle Cell Disease and Thalassemia

First-in-human trials of CRISPR-Cas12a gene editing demonstrate safety and meaningful event-free survival